{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T06:44:31Z","timestamp":1781851471373,"version":"3.54.5"},"reference-count":92,"publisher":"American Society of Hematology","issue":"10","license":[{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/legalcode"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Autoimmune conditions can occur in a temporary relationship with any malignant lymphoma. In many instances, treatment at diagnosis is not required, but symptomatic autoimmune conditions represent an indication for treatment, particularly in chronic lymphoproliferative diseases. Treatment is selected depending on the predominant condition: autoimmune disease (immunosuppression) or lymphoma (antilymphoma therapy). Steroids and anti-CD20 antibodies are effective against both conditions and may suppress the autoimmune complication for a prolonged period. The efficacy of B-cell receptor inhibitors has provided us with novel insights into the pathophysiology of antibody-producing B cells. Screening for underlying autoimmune conditions is part of the lymphoma workup, because other drugs, such as immunomodulators and checkpoint inhibitors, should be avoided or used with caution. In this article, we discuss diagnostic challenges and treatment approaches for different situations involving lymphomas and autoimmune cytopenias.<\/jats:p>","DOI":"10.1182\/blood.2019003686","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T21:59:34Z","timestamp":1631570374000},"page":"1479-1488","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["How I manage autoimmune cytopenias in patients with lymphoid cancer"],"prefix":"10.1182","volume":"139","author":[{"given":"Edit","family":"Porpaczy","sequence":"first","affiliation":[{"name":"Department of Medicine I, Division of Hematology and Hemostaseology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9826-1062","authenticated-orcid":false,"given":"Ulrich","family":"J\u00e4ger","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division of Hematology and Hemostaseology, and"},{"name":"Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2022050218125106600_B1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1365-2796.2008.02029.x","article-title":"Autoimmune and inflammatory disorders and risk of malignant lymphomas--an update","volume":"264","author":"Smedby","year":"2008","journal-title":"J Intern Med."},{"key":"2022050218125106600_B2","doi-asserted-by":"crossref","first-page":"102945","DOI":"10.1016\/j.critrevonc.2020.102945","article-title":"Lymphoma in the setting of autoimmune diseases: a review of association and mechanisms","volume":"150","author":"Khanmohammadi","year":"2020","journal-title":"Crit Rev Oncol Hematol."},{"issue":"8","key":"2022050218125106600_B3","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00277-011-1178-3","article-title":"Prevalence and clinical impact of autoimmune diseases and chronic infections in malignant lymphomas at diagnosis","volume":"90","author":"Vanura","year":"2011","journal-title":"Ann Hematol."},{"issue":"8","key":"2022050218125106600_B4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41408-018-0105-4","article-title":"History of autoimmune conditions and lymphoma prognosis","volume":"8","author":"Kleinstern","year":"2018","journal-title":"Blood Cancer J."},{"issue":"5","key":"2022050218125106600_B5","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.thromres.2014.08.021","article-title":"Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma","volume":"134","author":"Gebhart","year":"2014","journal-title":"Thromb Res."},{"issue":"6","key":"2022050218125106600_B6","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1080\/10428194.2017.1379075","article-title":"Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study","volume":"59","author":"Jachiet","year":"2018","journal-title":"Leuk Lymphoma."},{"issue":"6","key":"2022050218125106600_B7","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1080\/10428190701385173","article-title":"Autoimmune hemolytic anemias, Evans\u2019 syndromes, and pure red cell apl.asia in non-Hodgkin lymphomas","volume":"48","author":"Hauswirth","year":"2007","journal-title":"Leuk Lymphoma."},{"issue":"2","key":"2022050218125106600_B8","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/cancers12020282","article-title":"Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs","volume":"12","author":"Vitale","year":"2020","journal-title":"Cancers (Basel)."},{"issue":"2","key":"2022050218125106600_B9","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/leu.2015.273","article-title":"Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia","volume":"30","author":"Rogers","year":"2016","journal-title":"Leukemia."},{"issue":"8","key":"2022050218125106600_B10","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/10428190903026492","article-title":"Autoimmune cytopenia in chronic lymphocytic leukemia\/small lymphocytic lymphoma: changes in clinical presentation and prognosis","volume":"50","author":"Zent","year":"2009","journal-title":"Leuk Lymphoma."},{"issue":"1","key":"2022050218125106600_B11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2141.2011.08707.x","article-title":"Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment","volume":"154","author":"Hodgson","year":"2011","journal-title":"Br J Haematol."},{"issue":"11","key":"2022050218125106600_B12","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ajh.23785","article-title":"Autoimmune cytopenias in chronic lymphocytic leukemia","volume":"89","author":"Visco","year":"2014","journal-title":"Am J Hematol."},{"issue":"2","key":"2022050218125106600_B13","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1053\/j.seminoncol.2016.02.011","article-title":"Secondary autoimmune cytopenias in chronic lymphocytic leukemia","volume":"43","author":"Rogers","year":"2016","journal-title":"Semin Oncol."},{"issue":"3","key":"2022050218125106600_B14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3109\/10428190903556394","article-title":"Paraneoplastic autoimmune: cytopenias in Hodgkin lymphoma","volume":"51","author":"Lechner","year":"2010","journal-title":"Leuk Lymphoma."},{"issue":"7-8","key":"2022050218125106600_B15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00508-010-1319-z","article-title":"Autoimmune hemolytic anemia as a paraneoplastic phenomenon in solid tumors: a critical analysis of 52 cases reported in the literature [in German]","volume":"122","author":"Puthenparambil","year":"2010","journal-title":"Wien Klin Wochenschr."},{"issue":"1","key":"2022050218125106600_B16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/ejh.13239","article-title":"Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphoma","volume":"103","author":"Crickx","year":"2019","journal-title":"Eur J Haematol."},{"issue":"12","key":"2022050218125106600_B17","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.revmed.2019.03.328","article-title":"Cytop\u00e9nies auto-immunes associ\u00e9es au lymphome de Hodgkin : \u00e9tude r\u00e9trospective monocentrique [abstract in English]. [Autoimmune hemolytic anemia and immune thrombocytopenia associated with Hodgkin disease: retrospective monocentric study.]","volume":"40","author":"Car\u00e9","year":"2019","journal-title":"Rev Med Interne."},{"issue":"12","key":"2022050218125106600_B18","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood."},{"key":"2022050218125106600_B19","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/asheducation-2008.1.450","article-title":"Disease-specific complications of chronic lymphocytic leukemia","author":"Dearden","year":"2008","journal-title":"Hematol Am Soc Hematol Educ Program."},{"issue":"1","key":"2022050218125106600_B20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11899-017-0366-1","article-title":"A concise review of autoimmune cytopenias in chronic lymphocytic leukemia","volume":"12","author":"Tsang","year":"2017","journal-title":"Curr Hematol Malig Rep."},{"key":"2022050218125106600_B21","doi-asserted-by":"crossref","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev."},{"issue":"22","key":"2022050218125106600_B22","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1182\/blood-2016-11-693689","article-title":"How I treat autoimmune hemolytic anemia","volume":"129","author":"Go","year":"2017","journal-title":"Blood."},{"issue":"10","key":"2022050218125106600_B23","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1182\/blood.2019003808","article-title":"How I treat warm autoimmune hemolytic anemia","volume":"137","author":"Barcellini","year":"2021","journal-title":"Blood."},{"issue":"8","key":"2022050218125106600_B24","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ajh.20665","article-title":"Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia","volume":"81","author":"D\u2019Arena","year":"2006","journal-title":"Am J Hematol."},{"issue":"5","key":"2022050218125106600_B25","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1200\/JCO.1998.16.5.1885","article-title":"Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia","volume":"16","author":"Weiss","year":"1998","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022050218125106600_B26","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1365-2141.2007.06513.x","article-title":"Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors","volume":"136","author":"Borthakur","year":"2007","journal-title":"Br J Haematol."},{"issue":"4","key":"2022050218125106600_B27","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1365-2141.2007.06848.x","article-title":"Direct antiglobulin test negative autoimmune haemolytic anaemia associated with fludarabine\/cyclophosphamide\/rituximab therapy","volume":"139","author":"Garratty","year":"2007","journal-title":"Br J Haematol."},{"issue":"3","key":"2022050218125106600_B28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ajh.23909","article-title":"Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC\/MW and GOELAMS)","volume":"90","author":"Quinquenel","year":"2015","journal-title":"Am J Hematol."},{"issue":"8","key":"2022050218125106600_B29","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1182\/bloodadvances.2020001726","article-title":"Bendamustine-induced immune hemolytic anemia: a case report and systematic review of the literature","volume":"4","author":"Chan","year":"2020","journal-title":"Blood Adv."},{"issue":"6","key":"2022050218125106600_B30","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1080\/10428190902887563","article-title":"A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia","volume":"50","author":"Kaufman","year":"2009","journal-title":"Leuk Lymphoma."},{"issue":"3","key":"2022050218125106600_B31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/leu.2010.278","article-title":"Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia","volume":"25","author":"Rossignol","year":"2011","journal-title":"Leukemia."},{"issue":"4","key":"2022050218125106600_B32","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3109\/10428191003682767","article-title":"Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia\/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone","volume":"51","author":"Bowen","year":"2010","journal-title":"Leuk Lymphoma."},{"issue":"6","key":"2022050218125106600_B33","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00277-016-2643-9","article-title":"Bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal single-center study","volume":"95","author":"Kjellander","year":"2016","journal-title":"Ann Hematol."},{"issue":"5","key":"2022050218125106600_B34","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/bjh.13328","article-title":"Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia","volume":"170","author":"Manda","year":"2015","journal-title":"Br J Haematol."},{"issue":"11","key":"2022050218125106600_B35","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.3109\/10428194.2016.1154955","article-title":"Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion","volume":"57","author":"Cavazzini","year":"2016","journal-title":"Leuk Lymphoma."},{"issue":"3","key":"2022050218125106600_B36","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bjh.15545","article-title":"Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre","volume":"183","author":"Hampel","year":"2018","journal-title":"Br J Haematol."},{"issue":"2","key":"2022050218125106600_B37","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1038\/bcj.2017.5","article-title":"Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study","volume":"7","author":"Montillo","year":"2017","journal-title":"Blood Cancer J."},{"issue":"21","key":"2022050218125106600_B38","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.1182\/blood.V124.21.5654.5654","article-title":"Autoimmune hemolytic anemia and immune mediated thrombocytopenia in the phase III RESONATETM study of Ibrutinib vs Ofatumumab in relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma, including a case report [abstract]","volume":"124","author":"Montillo","year":"2014","journal-title":"Blood."},{"issue":"3","key":"2022050218125106600_B39","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3960\/jslrt.18012","article-title":"A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatment","volume":"58","author":"Suzuki","year":"2018","journal-title":"J Clin Exp Hematop."},{"issue":"6","key":"2022050218125106600_B40","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol."},{"issue":"9","key":"2022050218125106600_B41","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00277-017-3039-1","article-title":"Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p)","volume":"96","author":"Lacerda","year":"2017","journal-title":"Ann Hematol."},{"issue":"4","key":"2022050218125106600_B42","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.clml.2013.02.022","article-title":"Ofatumumab in rituximab-refractory autoimmune hemolytic anemia associated with chronic lymphocytic leukemia: a case report and review of literature","volume":"13","author":"Nader","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"5","key":"2022050218125106600_B43","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1034\/j.1600-0609.2003.00055.x","article-title":"Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath-1H","volume":"70","author":"Rodon","year":"2003","journal-title":"Eur J Haematol."},{"issue":"11","key":"2022050218125106600_B44","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/sj.leu.2403956","article-title":"Remission of pure red cell aplasia in T-cell receptor gammadelta-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab","volume":"19","author":"Sch\u00fctzinger","year":"2005","journal-title":"Leukemia."},{"issue":"2","key":"2022050218125106600_B45","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3324\/haematol.2017.175810","article-title":"Rational management approach to pure red cell aplasia","volume":"103","author":"Balasubramanian","year":"2018","journal-title":"Haematologica."},{"issue":"17","key":"2022050218125106600_B46","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","author":"Ghez","year":"2018","journal-title":"Blood."},{"issue":"17","key":"2022050218125106600_B47","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1182\/blood-2018-02-832154","article-title":"Ibrutinib and fungus: an invasive concern","volume":"131","author":"Rogers","year":"2018","journal-title":"Blood."},{"key":"2022050218125106600_B48","volume-title":"Hematology: Basic Principles.","author":"Michel","year":"2018","edition":"7th ed"},{"issue":"4","key":"2022050218125106600_B49","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood-2017-06-788463","article-title":"Hot therapy for cold agglutinin disease","volume":"130","author":"Jaeger","year":"2017","journal-title":"Blood."},{"issue":"3","key":"2022050218125106600_B50","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3324\/haematol.2013.091702","article-title":"Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma","volume":"99","author":"Randen","year":"2014","journal-title":"Haematologica."},{"issue":"3","key":"2022050218125106600_B51","first-page":"E184","article-title":"Cold agglutinin disease is a phenotypically distinct clonal B-cell disorder","volume":"15","author":"de Tute","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"5","key":"2022050218125106600_B52","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bjh.15063","article-title":"Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease","volume":"183","author":"Ma\u0142ecka","year":"2018","journal-title":"Br J Haematol."},{"issue":"11-12","key":"2022050218125106600_B53","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s00508-014-0547-z","article-title":"Cold antibody autoimmune hemolytic anemia and lymphoproliferative disorders: a retrospective study of 20 patients including clinical, hematological, and molecular findings [abstract in English] [Die autoimmunh\u00e4molytische An\u00e4mie vom K\u00e4ltetyp: eine retrospektive Analyse von 20 Patienten unter Ber\u00fccksichtigung klinischer, h\u00e4matologischer und molekularer Aspekte]","volume":"126","author":"Arthold","year":"2014","journal-title":"Wien Klin Wochenschr."},{"key":"2022050218125106600_B54","first-page":"2040620719873321","article-title":"Novel insights into the treatment of complement-mediated hemolytic anemias","volume":"10","author":"Be","year":"2019","journal-title":"Ther Adv Hematol."},{"issue":"3","key":"2022050218125106600_B55","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/bjh.15109","article-title":"How I manage patients with cold agglutinin disease","volume":"181","author":"Berentsen","year":"2018","journal-title":"Br J Haematol."},{"issue":"8","key":"2022050218125106600_B56","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood-2003-10-3597","article-title":"Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients","volume":"103","author":"Berentsen","year":"2004","journal-title":"Blood."},{"issue":"2","key":"2022050218125106600_B57","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/10428190500286481","article-title":"Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients","volume":"47","author":"Sch\u00f6llkopf","year":"2006","journal-title":"Leuk Lymphoma."},{"issue":"17","key":"2022050218125106600_B58","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1182\/blood-2010-06-288647","article-title":"High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease","volume":"116","author":"Berentsen","year":"2010","journal-title":"Blood."},{"issue":"4","key":"2022050218125106600_B59","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2017-04-778175","article-title":"Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial","volume":"130","author":"Berentsen","year":"2017","journal-title":"Blood."},{"issue":"4","key":"2022050218125106600_B60","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood.2020005674","article-title":"Cold agglutinin disease revisited: a multinational, observational study of 232 patients","volume":"136","author":"Berentsen","year":"2020","journal-title":"Blood."},{"issue":"5","key":"2022050218125106600_B61","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1182\/blood-2018-03-835413","article-title":"Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study","volume":"132","author":"Rossi","year":"2018","journal-title":"Blood."},{"issue":"9","key":"2022050218125106600_B62","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med."},{"issue":"15","key":"2022050218125106600_B63","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med."},{"issue":"1","key":"2022050218125106600_B64","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial [published correction appears in Lancet Oncol. 2019;20(1):e10]","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol."},{"issue":"9","key":"2022050218125106600_B65","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2018-06-856930","article-title":"Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial","volume":"133","author":"J\u00e4ger","year":"2019","journal-title":"Blood."},{"issue":"9","key":"2022050218125106600_B66","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2019-01-894303","article-title":"Cold agglutinins: fending off the attack","volume":"133","author":"Berentsen","year":"2019","journal-title":"Blood."},{"key":"2022050218125106600_B67","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdy146","article-title":"Waldenstr\u00f6m\u2019s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Kastritis","year":"2018","journal-title":"Ann Oncol."},{"issue":"8","key":"2022050218125106600_B68","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.3109\/10428194.2012.660628","article-title":"Autoimmune hemolytic anemia and autoimmune thrombocytopenia at diagnosis and during follow-up of Hodgkin lymphoma","volume":"53","author":"Dimou","year":"2012","journal-title":"Leuk Lymphoma."},{"issue":"23","key":"2022050218125106600_B69","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia [published correction appears in Blood Adv. 2020;4(2):252]","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv."},{"issue":"22","key":"2022050218125106600_B70","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv."},{"issue":"2","key":"2022050218125106600_B71","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/jcm6020016","article-title":"Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)","volume":"6","author":"Zufferey","year":"2017","journal-title":"J Clin Med."},{"issue":"12","key":"2022050218125106600_B72","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.3390\/jcm9123851","article-title":"Evans\u2019 syndrome: from diagnosis to treatment","volume":"9","author":"Audia","year":"2020","journal-title":"J Clin Med."},{"issue":"6","key":"2022050218125106600_B73","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00277-016-2642-x","article-title":"Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome","volume":"95","author":"Ca","year":"2016","journal-title":"Ann Hematol."},{"issue":"8","key":"2022050218125106600_B74","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood-2014-02-482612","article-title":"How we evaluate and treat neutropenia in adults","volume":"124","author":"Gibson","year":"2014","journal-title":"Blood."},{"issue":"7","key":"2022050218125106600_B75","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/sj.leu.2405077","article-title":"Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia","volume":"22","author":"Stamatopoulos","year":"2008","journal-title":"Leukemia."},{"issue":"11","key":"2022050218125106600_B76","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2169\/internalmedicine.56.7619","article-title":"A rare case of adult autoimmune neutropenia successfully treated with prednisolone","volume":"56","author":"Fujita","year":"2017","journal-title":"Intern Med."},{"issue":"10","key":"2022050218125106600_B77","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2010-07-296962","article-title":"How I treat LGL leukemia. [published correction appears in Blood. 2017;123(13):1182]","volume":"117","author":"Lamy","year":"2011","journal-title":"Blood."},{"issue":"9","key":"2022050218125106600_B78","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood-2013-03-491464","article-title":"Long-term remission of T-cell large granular lymphocyte leukemia associated with rheumatoid arthritis after rituximab therapy","volume":"122","author":"Cornec","year":"2013","journal-title":"Blood."},{"issue":"2","key":"2022050218125106600_B79","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000495600","article-title":"Autoimmune cytopenias occurring after treatment with chemoimmunotherapy for non-Hodgkin lymphomas","volume":"141","author":"Oka","year":"2019","journal-title":"Acta Haematol."},{"issue":"3-4","key":"2022050218125106600_B80","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00508-017-1285-9","article-title":"Review of cancer treatment with immune checkpoint inhibitors: current concepts, expectations, limitations and pitfalls","volume":"130","author":"Thallinger","year":"2018","journal-title":"Wien Klin Wochenschr."},{"issue":"1","key":"2022050218125106600_B81","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol."},{"issue":"11","key":"2022050218125106600_B82","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1159\/000481888","article-title":"Checkpoint inhibition in non-Hodgkin\u2019s lymphoma","volume":"40","author":"Hess","year":"2017","journal-title":"Oncol Res Treat."},{"issue":"1","key":"2022050218125106600_B83","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"issue":"15","key":"2022050218125106600_B84","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv."},{"issue":"9","key":"2022050218125106600_B85","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1365-2362.2009.02177.x","article-title":"Mechanisms underlying acquired von Willebrand syndrome associated with an IgM paraprotein","volume":"39","author":"Mayerhofer","year":"2009","journal-title":"Eur J Clin Invest."},{"issue":"8","key":"2022050218125106600_B86","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/MBC.0000000000000370","article-title":"Acquired factor VIII inhibitor and subsequent development of non-Hodgkin\u2019s lymphoma: a case report and review of the literature","volume":"26","author":"Porru","year":"2015","journal-title":"Blood Coagul Fibrinolysis."},{"issue":"9","key":"2022050218125106600_B87","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.3109\/10428194.2015.1131273","article-title":"Acquired C1 esterase inhibitor deficiency in lymphomas: prevalence, symptoms, and response to treatment","volume":"57","author":"Bekos","year":"2016","journal-title":"Leuk Lymphoma."},{"key":"2022050218125106600_B88","author":"Dufour","year":"2021"},{"issue":"4","key":"2022050218125106600_B89","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/annonc\/mdl467","article-title":"Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases","volume":"18","author":"W","year":"2007","journal-title":"Ann Oncol."},{"issue":"1","key":"2022050218125106600_B90","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/jcpt.12602","article-title":"Rapid decline in insulin antibodies and glutamic acid decarboxylase autoantibodies with ibrutinib therapy of chronic lymphocytic leukaemia","volume":"43","author":"Skrabs","year":"2018","journal-title":"J Clin Pharm Ther."},{"issue":"1","key":"2022050218125106600_B91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOH.0000000000000208","article-title":"How I diagnose and treat neutropenia","volume":"23","author":"Dale","year":"2016","journal-title":"Curr Opin Hematol."},{"issue":"3","key":"2022050218125106600_B92","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bjh.15581","article-title":"A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia","volume":"185","author":"Paul","year":"2019","journal-title":"Br J Haematol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/10\/1479\/1893444\/bloodbld2019003686c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/10\/1479\/1893444\/bloodbld2019003686c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T18:14:13Z","timestamp":1651515253000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/10\/1479\/476881\/How-I-manage-autoimmune-cytopenias-in-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":92,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,3,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019003686","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,10]]}}}